Triple-negative breast cancer: recent treatment advances.
Triple-negative breast cancer: recent treatment advances.
复制标题
DOI：
10.12688/f1000research.18888.1
复制
发表时间：
2019-01-01
期刊：
影响因子：
--
通讯作者：
Loi, Sherene
中科院分区：
文献类型：
--
作者：
Bergin, Alice R T;Loi, Sherene
三阴性乳腺癌（TNBC）是一种乳腺癌亚型，以其影响年轻女性的能力而闻名，尽管有最佳的辅助治疗，但早期转移，预后不良。新辅助治疗的重点是全身药物的组合，以优化病理完全缓解。治疗算法现在指导有或没有残留疾病的患者的管理，但转移性TNBC仍然具有不良预后。在新辅助和辅助治疗环境中，创新的多药物联合全身治疗已导致结局的显著改善，特别是在过去十年中。最近发表的治疗转移性TNBC的进展显示了使用聚（ADP-核糖）聚合酶（PARP）抑制剂和免疫治疗剂的令人印象深刻的结果。免疫治疗剂与传统的全身化疗相结合已被证明可以改变这种破坏性疾病的自然史，特别是在肿瘤对程序性细胞死亡配体1（PD-L1）呈阳性的患者中。
Triple-negative breast cancer (TNBC) is a breast cancer subtype renowned for its capacity to affect younger women, metastasise early despite optimal adjuvant treatment and carry a poor prognosis. Neoadjuvant therapy has focused on combinations of systemic agents to optimise pathological complete response. Treatment algorithms now guide the management of patients with or without residual disease, but metastatic TNBC continues to harbour a poor prognosis. Innovative, multi-drug combination systemic therapies in the neoadjuvant and adjuvant settings have led to significant improvements in outcomes, particularly over the past decade. Recently published advances in the treatment of metastatic TNBC have shown impressive results with poly (ADP-ribose) polymerase (PARP) inhibitors and immunotherapy agents. Immunotherapy agents in combination with traditional systemic chemotherapy have been shown to alter the natural history of this devastating condition, particularly in patients whose tumours are positive for programmed cell death ligand 1 (PD-L1).